KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Long-Term Debt Repayments (2021 - 2023)

Halozyme Therapeutics (HALO) has disclosed Long-Term Debt Repayments for 3 consecutive years, with -$13.5 million as the latest value for Q4 2023.

  • On a quarterly basis, Long-Term Debt Repayments rose 89.63% to -$13.5 million in Q4 2023 year-over-year; TTM through Sep 2024 was -$13.5 million, a 88.43% increase, with the full-year FY2025 number at $595.4 million, changed N/A from a year prior.
  • Long-Term Debt Repayments was -$13.5 million for Q4 2023 at Halozyme Therapeutics, down from -$17000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $369.1 million in Q1 2021 to a low of -$130.0 million in Q4 2022.
  • A 3-year average of $47.8 million and a median of -$17000.0 in 2023 define the central range for Long-Term Debt Repayments.
  • Biggest YoY gain for Long-Term Debt Repayments was 89.63% in 2023; the steepest drop was 89.63% in 2023.
  • Halozyme Therapeutics' Long-Term Debt Repayments stood at $369.1 million in 2021, then tumbled by 135.22% to -$130.0 million in 2022, then skyrocketed by 89.63% to -$13.5 million in 2023.
  • Per Business Quant, the three most recent readings for HALO's Long-Term Debt Repayments are -$13.5 million (Q4 2023), -$17000.0 (Q2 2023), and $13.5 million (Q1 2023).